Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

Sana CEO Steve Harr (Sana photo)

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street.

It plans to trade on Nasdaq under the ticker SANA, with a goal of raising up to $150 million.

Sana, which is developing gene and cell therapies that could be used to combat a variety of diseases, previously raised more than $700 million in venture capital, making it one of the most

Lead Generation

This post was originally published on this site


Check out
%d bloggers like this: